{"organizations": [], "uuid": "a0ea697935bd8c1bed7d128e44278e9965dd5e0f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180524.html", "section_title": "Archive News &amp; Video for Thursday, 24 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-omeros-says-entered-into-settlemen/brief-omeros-says-entered-into-settlement-agreement-and-consent-judgment-with-lupin-ltd-and-unit-lupin-pharmaceuticals-sec-filing-idUSFWN1SV0GL", "country": "US", "domain_rank": 408, "title": "BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.361, "site_type": "news", "published": "2018-05-24T20:28:00.000+03:00", "replies_count": 0, "uuid": "a0ea697935bd8c1bed7d128e44278e9965dd5e0f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-omeros-says-entered-into-settlemen/brief-omeros-says-entered-into-settlement-agreement-and-consent-judgment-with-lupin-ltd-and-unit-lupin-pharmaceuticals-sec-filing-idUSFWN1SV0GL", "ord_in_thread": 0, "title": "BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "sec", "sentiment": "negative"}, {"name": "lupin ltd", "sentiment": "negative"}, {"name": "lupin pharmaceuticals", "sentiment": "negative"}, {"name": "reuters) - lupin ltd", "sentiment": "neutral"}, {"name": "omeros corp", "sentiment": "none"}, {"name": "omidria", "sentiment": "none"}, {"name": "lupin", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 24 (Reuters) - Lupin Ltd:\n* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING\n* OMEROS - AGREEMENT RESOLVES CO’S PATENT LITIGATION AGAINST LUPIN\n* OMEROS CORP - LUPIN ACKNOWLEDGED & CONFIRMED VALIDITY OF EACH OF PATENTS LISTED IN ORANGE BOOK FOR OMIDRIA\n* OMEROS CORP - PARTIES EXECUTED CONSENT JUDGMENT THAT WAS FILED WITH COURT FOR DISTRICT ON MAY 23, 2018\n* OMEROS - LUPIN GRANTED LICENSE TO MAKE, SELL GENERIC VERSION OF OMIDRIA BETWEEN PERMITTED LAUNCH DATE & LATEST EXPIRATION OF CO’S U.S. PATENTS\n* OMEROS CORP - LUPIN IS GRANTED NON-EXCLUSIVE, NON-SUBLICENSABLE WAIVER OF CO'S PEDIATRIC EXCLUSIVITY FOR OMIDRIA UNTIL AT LEAST APRIL 23, 2034 Source text: ( bit.ly/2GKSJ0y ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2GKSJ0y", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-05-24T20:28:00.000+03:00", "crawled": "2018-05-25T16:14:10.010+03:00", "highlightTitle": ""}